Abstract
Off-the-shelf T and NK cell-based strategies are the of future allogeneic cellular therapies, as they overcome most of the current limitations associated with classical CAR-T cell therapies. The source of cells for off-the-shelf T or NK products will likely be diverse due to leveraging distinct attributes of different effector cell types (blood, cord blood, and iPSC) currently in development. Technological advances in synthetic biology have yielded a diverse set of chimeric antigen receptors, engineered cytokine support, and gene edits that improve the feasibility, activity, and safety of allogeneic T and NK cell therapies. One barrier to the success of allogeneic T and NK cell therapies is recognition and rejection by the patients’ immune systems, and strategies to make stealth off-the-shelf cell therapies are under investigation.
Original language | English |
---|---|
Title of host publication | Precision Cancer Therapies |
Subtitle of host publication | Volume 2: Immunologic Approaches for the Treatment of Lymphoid Malignancies: From Concept to Practice |
Publisher | wiley |
Pages | 341-359 |
Number of pages | 19 |
ISBN (Electronic) | 9781119824572 |
ISBN (Print) | 9781119824541 |
DOIs | |
State | Published - Jan 1 2024 |
Keywords
- CAR T cell
- GVHD
- NK Cell
- Off the Shelf
- allogeneic cell
- cellular therapy
- gene editing technology